Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Express Scripts
Merck

Last Updated: September 25, 2022

ELIGARD KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Eligard Kit, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar Therap and is included in four NDAs. There is one patent protecting this drug.

This drug has sixty-eight patent family members in twenty-six countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4th, 1998.

  Try it Free

Summary for ELIGARD KIT
International Patents:68
US Patents:1
Applicants:1
NDAs:4
Finished Product Suppliers / Packagers: 1
Clinical Trials: 48
Formulation / Manufacturing:see details
DailyMed Link:ELIGARD KIT at DailyMed
Drug patent expirations by year for ELIGARD KIT
Recent Clinical Trials for ELIGARD KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tolmar PharmaceuticalsPhase 2
National Institute on Aging (NIA)Phase 2
Weill Medical College of Cornell UniversityPhase 2

See all ELIGARD KIT clinical trials

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by one US patents.

Patents protecting ELIGARD KIT

Sustained release polymer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING CANCER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tolmar Therap ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021343-001 Jan 23, 2002 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tolmar Therap ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Tolmar Therap ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Tolmar Therap ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELIGARD KIT

International Patents for ELIGARD KIT

See the table below for patents covering ELIGARD KIT around the world.

Country Patent Number Title Estimated Expiration
Norway 920302 See Plans and Pricing
Japan 2014240439 改良された効力を備えた、ロイプロリドのポリマー送達処方物 (POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY) See Plans and Pricing
Denmark 1267965 See Plans and Pricing
Hungary 228386 Javított hatékonyságú leuprolid polimeres bejuttatására szolgáló készítmények (POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY) See Plans and Pricing
Hong Kong 1141459 See Plans and Pricing
Denmark 57291 See Plans and Pricing
Portugal 1126822 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
Boehringer Ingelheim
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.